Abstract
Background. In absence of prophylaxis, HBV recurrence after liver transplantation (LT) develops in up to 75% of cases. The use of hepatitis B immune globulins (HBIG) in combination with nucleoside analogues (NA) has improved outcomes of LT for HBV, reducing the 1-year recurrence rate to approximately 10%. In originally HBsAg-positive recipients of LT, HBIG schedule should be aimed to maintain HBsAg negative and anti-HBs serum titer >100IU/l after surgery.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
